FDA CDER Letter to U.S. Patent Office

This document is a notice of a letter sent from the FDA's Center for Drug Evaluation and Research (CDER) to the U.S. Patent and Trademark Office. The letter is dated March 19, 2026, and is available for public viewing on Regulations.gov. The specific content of the letter is not detailed in the provided information, but its existence indicates a communication between these two federal agencies regarding matters relevant to drug development and intellectual property.

As this is a routine notice of correspondence, there are no immediate compliance actions required for regulated entities. Compliance officers should note the existence of this communication for awareness regarding potential inter-agency discussions that may impact pharmaceutical and patent law. No specific deadlines or penalties are associated with this notice.